Clinical Utility of MyProstateScore 2.0 P2

Prostate Cancer Clinical Trial

Official title:

An Extension Study of LynxDx's Ongoing Determination of Clinical Utility of MyProstateScore 2.0 Test: A Combined CPV-Based, Patient-Level Assessment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05910697
• Other study ID #: Pro00070241
• Status: Terminated
• Phase: N/A
• Start date: March 31, 2023
• Est. completion date: October 18, 2023

Study information

• Verified date: November 2023
• Source: Qure Healthcare, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an extension of an ongoing study. Preliminary results from the ongoing study indicate that the MyProstateScore 2.0 (MPS 2.0) Test is significantly improving early diagnosis of prostate cancer. This extension will allow us to ask the study participants in the ongoing study to share patient-level data for chart abstraction. The specific purpose of this study is to generate high-quality real-world data on the clinical utility of LynxDx's new MPS 2.0 test.

Description:

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidelines. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 150 physicians. Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPVs describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis, and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and the investigators estimate the time commitment for each round of CPV administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. They will also be asked to submit de-identified charts for patients who meet eligibility criteria. Physicians will keep their randomization from the ongoing study, and intervention physicians will have the opportunity to order a diagnostic test for their patients free of charge.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 142
• Est. completion date: October 18, 2023
• Est. primary completion date: October 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Licensed urologist
• Have practiced as a urologist for greater than 2 but less than 40 years
• Commonly treats patients at risk for prostate cancer
• Practicing in the United States
• English-speaking
• Access to the internet
• Informed and voluntarily consented to be in the study

Exclusion Criteria:

• Non-English speaking
• Not a licensed primary care provider
• Unable to access the internet
• Not practicing in the U.S.
• Do not voluntarily consent to be in the study

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• MyProstateScore 2.0 Results
Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.

Locations

Country	Name	City	State
United States	QURE Healthcare	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Qure Healthcare, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Baseline levels of variation in the assessment, surveillance, and management of patients at high risk for prostate cancer among all study participants.	Using the responses of the CPV cases as well as abstracted chart data to measure the baseline levels of variation in the work-up, recognition, and management of prostate cancer. Work-up, recognition, and management scores will be combined to report variation in total assessment of the simulated patient cases.	[9 months]
Primary	Pre- and post-comparison of overall diagnostic and treatment scores between Control physicians (using standard of care diagnostic tools) and Intervention physicians (with access to the MyProstateScore 2.0 test).	Measure of overall CPV scores between arms using standard of care measurements between the control and intervention arms.	[9 months]
Primary	Differences in evidence-based decision making	Differences in the number of evidence-based decisions made by intervention physicians versus control physicians (such as prescribing pharmaceuticals or non-pharmacologic interventions), while statistically controlling for physician and practice characteristics, between rounds 1 and 2.	[9 months]
Primary	Differences in expected cost of care between control and intervention physicians.	Difference in the cost of care between control and intervention participants (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs per above).	[9 months]
Primary	Differences in management of patients at risk of prostate cancer.	Differences between control and intervention patients in the quality of counseling, utilization of biopsies/scheduled biopsies, referrals, imaging studies, and reported symptoms. As measured by the number of times each item is seen in the collected data.	[9 months]
Primary	Differences between expected quality of care and actual quality of care	Measure any discrepancy in clinical quality metrics and by different use case types. Measured by number of evidence-based decisions seen in medical chart abstraction.	[9 months]